⚠️ All products are sold strictly for research purposes only — not for human or veterinary use
    Wild Ginger Peptides
    Back to Shop

    BPC-157 Research Overview

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a sequence of 15 amino acids — that has been extensively studied in preclinical research for its effects on tissue repair mechanisms, angiogenesis, and inflammatory modulation. The compound is derived from a partial sequence of a naturally occurring gastric protein known as Body Protection Compound, which has been identified in human gastric juice.

    This article provides an overview of the published scientific literature on BPC-157, summarising the key findings from laboratory and preclinical studies. All information is presented in the context of research investigation — BPC-157 is a research compound and is not approved for any therapeutic, medical, or veterinary application.

    Molecular Properties

    BPC-157 has the following molecular characteristics:

    • Amino acid sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
    • Molecular formula: C₆₂H₉₈N₁₆O₂₂
    • Molecular weight: approximately 1419.5 Da
    • Stability: notably stable in acidic conditions and human gastric juice — an unusual property for a peptide of this size

    The peptide is typically supplied as a lyophilised powder and is soluble in bacteriostatic water and sterile water at standard research concentrations. View our BPC-157 product page for specifications.

    Published Research Areas

    BPC-157 has been the subject of numerous peer-reviewed publications, primarily examining its effects in cell culture models and animal studies. The major research themes include:

    Tissue Repair and Regeneration

    Multiple preclinical studies have investigated BPC-157's effects on various tissue types. Research has reported accelerated healing responses in models involving tendon, ligament, muscle, and bone tissue. The peptide has been studied in the context of tendon-to-bone healing, where it appeared to promote collagen organisation and neovascularisation at the repair site.

    Studies examining muscle healing have reported enhanced remodelling processes and improved functional recovery in laboratory models. Research on bone tissue has investigated the peptide's effects on fracture healing and osteogenic differentiation.

    Angiogenesis

    Several studies have investigated BPC-157's effects on blood vessel formation. Research has demonstrated increased expression of vascular endothelial growth factor (VEGF) and enhanced tubulogenesis in endothelial cell models. The peptide has been studied for its potential pro-angiogenic mechanisms, including effects on the VEGF receptor pathway and nitric oxide synthase (NOS) signalling.

    Nitric Oxide System Interactions

    Research has explored the relationship between BPC-157 and the nitric oxide (NO) system. Studies suggest that the peptide may modulate NO pathways, with some investigations reporting interactions with both the constitutive (eNOS) and inducible (iNOS) forms of nitric oxide synthase. The directionality of these effects appears to depend on the experimental context.

    Gastrointestinal Research

    Given its derivation from a gastric protein, BPC-157 has been extensively studied in gastrointestinal models. Research has examined its effects on gastric lesion models, intestinal anastomosis healing, and inflammatory bowel models. The peptide's stability in gastric juice has made it particularly interesting for studies examining oral administration routes in animal models.

    FAK-Paxillin Pathway

    Recent research has investigated BPC-157's interactions with the focal adhesion kinase (FAK)-paxillin signalling pathway, which is involved in cell adhesion, migration, and tissue remodelling. Studies have reported increased phosphorylation of FAK and paxillin in cell culture models treated with BPC-157, suggesting potential involvement in cell migration and wound closure mechanisms.

    Methodological Considerations

    When evaluating the BPC-157 research literature, several methodological points merit consideration:

    • The majority of published studies are preclinical — conducted in cell culture systems or animal models. The findings cannot be directly extrapolated to other contexts.
    • Much of the published research originates from a relatively small number of research groups, which is a consideration when assessing the breadth of independent replication.
    • Dosing protocols, administration routes, and experimental models vary significantly across studies, making direct comparison of results challenging.
    • As with all peptide research, the purity and identity of the compound used is critical. Studies should ideally report analytical verification data for the peptide employed.

    Handling BPC-157 in the Laboratory

    BPC-157 is supplied as a lyophilised powder and should be reconstituted in bacteriostatic water or sterile water prior to use. The peptide is readily soluble in aqueous solvents at standard research concentrations.

    • Storage (lyophilised): -20°C or below, protected from moisture and light
    • Storage (reconstituted): 2–8°C, use within 14 days
    • Reconstitution solvent: bacteriostatic water (recommended) or sterile water
    • Aliquoting: recommended to avoid repeated freeze-thaw cycles

    For detailed protocols, see our Peptide Reconstitution Guide and Storage and Handling Guide.

    Related Products and Resources

    Research Use Disclaimer: Products sold by WG Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or any therapeutic applications. By purchasing, you confirm that you are acquiring these products solely for legitimate research purposes.